1. HCV treatment outcome depends on SNPs of IFNL3-Gene polymorphisms (rs12979860) and cirrhotic changes in liver parenchyma
- Author
-
Mohamed Darwish Ahmed Abd Alla, Reham M. Dawood, Hassan Abd EL-Hafeth Rashed, Yasser Mohammed El-Dessouky, Galal AbdElhameed AbuFarrag, Islam Abdelmawla Emran Ammar, Mohamed Mahmoud Abdel-Halim Mahmoud, Ghada M. Salum, Mohamed Zakaria Abu-Amer, Mohamed Abd elrafaa Hassan Sekeen, Mohamed Mousa Ibraheem Heggazy, Ahmed Mohamed Abdulhamid Altanbouly, Mai Abd El-Meguid, and Mostafa K. El Awady
- Subjects
IFNL3-Gene-SNPs ,DAAs ,PBMCs-PCR ,HCV-Hepatic-changes ,Science (General) ,Q1-390 ,Social sciences (General) ,H1-99 - Abstract
Background and objective: The allelic discrimination of IFNL3-(rs12979860 C > T) polymorphism reveals ambiguous associations with the effectiveness of oral HCV treatment. Solitary intra peripheral-blood-mononuclear-cells (PBMCs) HCV-RNA antisense-strands are independently detected in naïve and experienced cases regardless of viremia or hepatic-parenchymal alterations. We examined the frequencies of IFNL3-genetic variants with chronic-HCV-induced liver changes during the sustained virologic response (SVR) by evaluating the PBMCs- HCV-PCR after oral antiviral therapy. Methods: Twelve weeks after finishing oral antiviral therapy, the effects of IFNL3-genetic variants were evaluated in three groups of patients: Group-I (n = 25) showed HCV-RNA negativity in both serum and PBMCs-, group II (n = 52) showed positivity of HCV-RNA in PBMCs, and group-III (n = 25) had positive HCV-RNA in serum. The genetic variants of the IFNL3-gene were estimated for all the enrolled cases and correlated with their hepatic image changes. Results: IFNL3-(rs12979860) genotyping in post-direct acting antivirals (DAAs) SVR and HCV-relapse revealed: a) high frequency of CC-genotype and C-allele in group I compared to group II (P
- Published
- 2023
- Full Text
- View/download PDF